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Abstract
Background: In April 2009, public health surveillance detected an increased number of influenza-like illnesses in
Mexico City’s hospitals. The etiological agent was subsequently determined to be a spread of a worldwide novel
influenza A (H1N1) triple reassortant. The purpose of the present study was to demonstrate that molecular
detection of pandemic influenza A (H1N1) 2009 strains is possible in archival material such as paraffin-embedded
lung samples.
Methods: In order to detect A (H1N1) virus sequences in archived biological samples, eight paraffin-embedded
lung samples from patients who died of pneumonia and respiratory failure were tested for influenza A (H1N1)
Neuraminidase (NA) RNA using in situ RT-PCR.
Results: We detected NA transcripts in 100% of the previously diagnosed A (H1N1)-positive samples as a
cytoplasmic signal. No expression was detected by in situ RT-PCR in two Influenza-like Illness A (H1N1)-negative
patients using standard protocols nor in a non-related cervical cell line. In situ relative transcription levels correlated
with those obtained when in vitro RT-PCR assays were performed. Partial sequences of the NA gene from A
(H1N1)-positive patients were obtained by the in situ RT-PCR-sequencing method. Sequence analysis showed 98%
similarity with influenza viruses reported previously in other places.
Conclusions: We have successfully amplified specific influenza A (H1N1) NA sequences using stored clinical
material; results suggest that this strategy could be useful when clinical RNA samples are quantity limited, or when
poor quality is obtained. Here, we provide a very sensitive method that specifically detects the neuraminidase viral
RNA in lung samples from patients who died from pneumonia caused by Influenza A (H1N1) outbreak in Mexico
City.
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Background
During April 2009, the number of atypical pneumonia
cases increased in Mexico City’s hospitals and spread to al-
most all boroughs in the city; these cases were related to a
new influenza A (H1N1) virus strain that was identified as
the etiological agent [1-4]. In less than a month the virus
spread worldwide and on June 11, 2009 the World Health
Organization (WHO) declared the start of the first 21st
century influenza pandemic.
Influenza A viruses belong to the Orthomyxoviridae fa-
mily; they are characterized by a unique genome structure
with a single-negative RNA strand, which codifies, among
others, for two transmembrane proteins: hemagglutinin
(HA) and neuraminidase (NA) [5-7]. HA plays an impor-
tant role during the cell entry of influenza viruses. This pro-
tein is essential during the initial steps of infection because
it is responsible for the attachment of the virus to sialic acid
(SA) cellular receptor. This interaction explains, at least in
part, the host range and tissue tropism of influenza viruses
[5,8]. The NA of influenza viruses is a homotetrameric
glycoprotein anchored by a fibrous stalk in the viral mem-
brane. The protein possesses a globular head comprised of
four monomers that constitute the active site composed of
nine conserved residues. Its primary role in the infectious
cycle is to liberate the viral progeny from infected cells. Its
enzymatic activity catalyzes SA removal from its linkage to
galactose, thereby destroying the receptor and allowing the
virus to disseminate and infect other cells [8,9]. Further-
more, NA is also the main target of the antiviral drugs
zanamivir and oseltamivir. These drugs closely resemble
the structure of the natural substrate of the NA and thus
prevent the removal of the SA residue from the glycopep-
tide receptor by the viral neuraminidase [5]. In addition to
the increased transmissibility and the low or lack of im-
munity of the human population, the fact that new rea-
ssortment events may alter the pathogenicity of circulating
strains, makes it crucial to monitor the progress of the pan-
demics at the molecular level [2,10,11].
Molecular methods are becoming more widely used for
the detection of respiratory pathogens, in part because of
their superior sensitivity, relatively rapid turnaround time,
and ability to identify pathogens that are slow growing or
difficult to culture. The recent novel H1N1 influenza A
pandemic has been useful to underscore how quickly new
molecular tests can become available for clinical use [12].
Previously, several groups have been used immunohisto-
chemical or immunofluorescence detection for determine
the localization of influenza virus antigens, as well as in
situ hybridization for detection of viral sequences and
ultrastructural examination to detect viral particles, in
cases of fatal H1N1 influenza A virus infection during the
period 2009–2010 [13-19]. These analyses were performed
on sections from different tissues such as respiratory
tissues (trachea, lung), heart, liver, and placenta [13-19].
Over the years, Reverse-transcriptase PCR is the recom-
mended test for diagnosis and confirmation of infections
due to pandemic 2009 influenza A(H1N1) virus [20].
Recently, modifications of this technology have emerged,
some of which allow the rapid detection of multiple
pathogens in a single test such as multiplex molecular
technologies, reverse transcriptase-PCR, real-time PCR,
microarrays and nucleic acid sequencing-based amplifica-
tions [12,21,22]. Other studies have also shown the useful-
ness of rapid immunoassays for seasonal influenza virus
[23]. These methods have greatly enhanced the capability
for surveillance and characterization of influenza viruses
and their clinical utility for the detection of respiratory
pathogens. However, these methods can not be easily
applied for the analysis of paraffin-embedded tissues. In
situ RT-PCR has some major strengths for the detection
of specific nucleic acid sequences. First and foremost, one
can detect particular sequences on archival material; se-
cond, this technique combines the extreme sensitivity of
PCR with the cell localization ability similar to in situ
hybridization [17]. A third strength of in situ RT-PCR
relates to the issue of sample contamination in solution-
phase PCR. Sample contamination, which can lead to
false-positive results in PCR, limits its value as a diagnostic
test for viral infections; this limitation is not encountered
in in situ RT-PCR. Fourth, this technique is the only
amplification technique that allows direct target-specific
incorporation of a reporter nucleotide (such as DIG-
digoxigenin-dUTP-labeled nucleotide) [24,25], thus elim-
inating the need for a hybridization step. Clearly, in situ
RT-PCR has been useful for any target that is low copy
and, thus, difficult to detect with standard in situ
hybridization, which has a detection threshold of 10 to 20
copies per cell [17].
The purpose of the present study was to demonstrate
that sensitive and specific molecular detection of pan-
demic influenza A (H1N1) 2009 strains is possible in
archival material such as paraffin-embedded lung sam-
ples. This strategy would be useful to perform current




This project was approved after being checked by the “In-
stitute Science and Bioethics Committee” (INER-Mexico).
The Committee is responsible for evaluating the research
projects to be performed, in order to monitor that every
study meets the principles for research involving human
subjects, established in the Declaration of Helsinki and its
different revisions. The approval number is: B07-09.
From April 2009 to February 2010, eight lung samples
were taken post mortem from patients who died of pneu-
monia and respiratory failure at Instituto Nacional de
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Enfermedades Respiratorias-Ismael Cosío Villegas (INER)
and Clinica-32 of Instituto Mexicano del Seguro Social
(IMSS), Mexico City. At least three autopsy samples were
collected mainly from medium upper lobe of the lung
(Table 1). The size of lung autopsy samples ranged from
20 to 80 mm2 area. Lung samples were paraffin-embedded,
sectioned to obtain 5 μm thick sections and mounted
on electrostatically charged slides. Molecular procedures
(RT-PCR, in situ RT-PCR, sequencing and in vitro duplex
amplification technique) were performed in all 8 patient
lung samples, as well as in control samples. All specimens
were studied by an expert pathologist (R.M.R.R.).
Molecular detection of A (H1N1) viruses
The detection of pandemic influenza A (H1N1) 2009
viruses was done using RT-PCR standard protocols
as part of the Virology Department’s surveillance
routine and has been described elsewhere (http://
www.who.int/csr/resources/publications/swineflu/real-
timeptpcr/en/index.html; [2,26]). All specimens were
accompanied by a standard form with information
about age, sex, date of illness onset, date of speci-
men collection, place of residence, clinical features
of each patient, travel history, vaccination history
and administration of antiviral treatment.
Primers
Neuraminidase (NA) specific primer sequences were
selected according to the need of the in situ technique:
NA/AH1N1F (sense) 5’-ACCATTGGTTCGGTCTGTA
TG-3’ and NA/AH1N1R (antisense): 5’-GAGGCCTGT
CCATTACTTGGPU-3’. These primers have been pre-
validated by liquid-phase RT-PCR method that allows
the detection of a 729 base pairs (bp) band in agarose
gel electrophoresis on clinical samples obtained from
patients infected with A (H1N1) (Manjarrez-Zavala et al.,
manuscript in preparation). As internal constitutive ex-
pression control, β2-microglobulin (β2-m) transcripts
were detected using the following primers: β2mF (sense):
5’-ACCCCCACTGAAAAAGATGAGTAT-3’ and β2mR
(antisense): 5′-ATGATGCTGCTTACATGTCTCGAT-
3′ [27-29]. β2-m PCR size product was of 100 bp. All pri-
mers were purchased from Invitrogen (U.S.A.).
In situ RT-PCR
Direct in situ RT-PCR was performed as previously
described with some modifications [24,25,30-32] (Figure 1).
Briefly, dried dewaxed sections on electrostatically charged
slides were incubated with protein lysis buffer (0.1 M Tris–
HCl pH 8.0, 50 mM EDTA pH 8.0) containing 0.5 μg/ml
Proteinase K for 30 min at room temperature. After
Proteinase K digestion, each tissue section was treated with
50 μl of a solution containing 1 U of DNase I, RNase-free
(Roche, U.S.A.) during 48 h at room temperature. After
thoroughly washing with DEPC-treated water, in situ re-
verse transcription was performed using the SuperScript II
reverse transcriptase (Invitrogen, U.S.A.), following the
manufacturer’s specifications. In brief, 70 μl DEPC-treated
water containing 3 μg of random primers oligonucleotides
(mostly hexamers; Invitrogen, U.S.A.), 10 mM dNTP mix
(10 mM each dATP, dGTP, dCTP and dTTP at neutral
pH), 5X first-strand buffer, 10 mM DTT, recombinant
ribonuclease inhibitor (40 U/μl) and reverse transcriptase
(100 U/ tissue section) (Invitrogen, U.S.A.) were added to
each section. Slides were incubated at 42°C for 1 h in a
sealed humidified chamber. After thoroughly washing with
ultrapure water, 50 μl of the PCR master mix solution
containing 100mM digoxigenin-11-(2'-deoxy-uridine-5')-
triphosphate (DIG-11-dUTP; Roche, U.S.A.), 10X PCR
buffer, 50 mM MgCl2 and primer mix (10 μM each of for-
ward and reverse primers) were added [31]. To reduce
primer-dimer formation the PCR solution was heated to
70°C for 10 min before Taq DNA polymerase (5 U per
reaction) was added. Negative controls included tissue
obtained from two Influenza-like Illness (ILI) patients that
were negative for the influenza A (H1N1) virus. These A
(H1N1) negative patients showed: (1) severe acute respira-
tory illness defined as dyspnea plus bilateral infiltrates on
the x-ray; (2) lack of 2009 H1N1 infection; and (3) a stay of
at least 24 h in the intensive care units. Samples were taken
after patients died. In addition, reactions without primers
or reactions without Taq DNA polymerase were performed
in consecutive tissue sections from all samples. In situ PCR
was performed using the system provided by Perkin Elmer
(U.S.A.). Fifty microliters of PCR master mix were added
to each sample and the reaction was sealed using Ampli-
Cover discs and clips (Perkin Elmer, U.S.A.). After assem-
bly, slides were placed at 70°C in the GeneAmp In situ
PCR system 1000 (Perkin Elmer, U.S.A.) until running was
started (18 cycles). Amplifications for NA or β2-m were
performed separately. Samples were first heated to 94°C
(3 min) and then subjected to 18 cycles of: 94°C/ 1 min,
60°C/ 1.5 min and 72°C/ 1 min. After amplification a
10-min elongation step at 72°C was carried out. After
Table 1 List of autopsy samples obtained from A H1N1
positive patients




P01 Central and peripheral 30 3
P02 Central 24 4
P03 Central 40 3
P04 Central and peripheral 20 4
P05 Central 24 3
P06 Central 80 3
P07 Central and peripheral 66 2
P08 Central and peripheral 72 3
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cycling was complete, the temperature was kept at 4°C
until disassembly. Clips were removed and AmpliCover
discs were very carefully lifted from the slides without
moving them sideways and slides were washed for 5 min
in PBS followed by 5 min in 100% EtOH before they
were air dried [30]. To ensure consistency and reprodu-
cibility and to eliminate PCR artifacts, all assays were
performed on a minimum of three separate occasions.
Slides were processed in order to detect in situ PCR
products (see below).
Detection of in situ PCR products
An indirect immunolabeling method using a primary Anti-
Digoxigenin antibody (Fab fragments; Roche, U.S.A.) con-
jugated to alkaline phosphatase was chosen to detect the
PCR product. Briefly, blocking was carried out in 5% BSA
(Sigma, U.S.A.) in PBS for 30 min. Slides were then drained
and incubated with Anti-DIG antibody diluted 1:200 in
100 mM Tris–HCl pH 7.4 and 150 mM NaCl (100 μl per
sample) for 2 h at room temperature. As negative control
the primary antibody was omitted. Detection of alkaline
phosphatase was carried out for 10–30 min using NBT/
BCIP kit (Zymed, U.S.A.). After detection, slides were
rinsed in distilled water for 5 min and air dried before
mounting in Permount histological mounting medium
(Fisher Scientific, U.S.A.).
Digital Image Capture, analysis and quantification
All photomicrographs were obtained using a DFC290 HD
digital camera (Leica Microsystems, USA). The following
method of quantification was used for in situ RT-PCR
analyses. After acquisition of the images using the digital
camera, the experimental image files were opened in the
PhotoImpact software (Ulead PhotoImpact SE version
3.02; Ulead Systems, U.S.A.). The images were digitally
processed in order to obtain the better and homogeneous
signal and then selected for analysis of relevant regions.
The selected regions were then digitally analyzed using
the Image-ProPlus Analysis Software (Ver 4.5.0.19, Media
Cybernetics, Inc., U.S.A.). The amount of signal was quan-
tified using a pixel matrix data (the color contained within
a pixel inside an image at specific location). Therefore,
chromogen quantity was determined by calculating the
norm of the matrix file for that image. This allows pixels
of similar “color” immediately adjacent to the index pixel
to be included for analysis. All pixels falling within the
selected threshold parameters were quantified, recorded
and used to generate a graphic. The file for the control
image was similarly generated: the control slide is acquired
Figure 1 Experimental design used to detect the Neuraminidase-gene derived nucleic acid of A (H1N1) virus by in situ RT-PCR. Tissue
fixed on electrostatically charged slides (1) was permeabilized and genomic DNA was eliminated using RNase-free DNase (2). After in situ reverse
transcription (3), synthesized cDNA was amplified and detected on tissue (4). Reverse Transcription reaction product was recovered for
amplification using in vitro PCR and subsequent sequencing (5) and quantification by Real Time quantitative PCR (RTqPCR) (6).
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and treated identically as the experimental slide. Negative
controls included: Two A (H1N1)-negative samples, reac-
tions without reverse transcriptase and reactions without
anti-DIG antibody. Beta2-microglobulin signal was used
to normalize data in case of in situ RT-PCR quantification.
Sequencing of in situ RT-PCR products
After in situ reverse transcription, solution over the
tissue section was recovered and the cDNA contained
in this solution was amplified using standard liquid-
phase PCR. The nucleotide sequences of the PCR
products were determined using the BigDye Terminator
v 3.1 Cycle sequencing kit (Applied Biosystems), puri-
fied using the ZR DNA Sequencing Clean-up Kit (Zymo
Research Corp. U.S.A.) and analyzed on the ABI Prism
310 Analyzer Sequencer (Applied Biosystems). The
obtained sequences were aligned and analyzed using Basic
Local Alignment Search Tool (BLAST; http://blast.ncbi.
nlm.nih.gov). Sequences obtained from amplification cor-
responded to the segment between the middle part and
the 3’ end of the NA gene (Figure 1). We have included
two positive controls: a Puerto Rico/Puerto Rico/IvPR8/
Puerto Rico laboratory strain and an A (H1N1) positive
sample obtained from a patient with Influenza A virus A/
reassortant/NYMC X-179 (California/07/2009 × NYMC
X-157) (H1N1) (GenBank: CY058512.1) (Tables 2 and 3).
In vitro Duplex amplification technique
In vitro duplex amplifications were performed using 2 μL
of cDNA as template and reaction mixtures (25 μL) con-
taining: 1x PCR buffer, 1.5 mM of MgCl2, 200 μM of each
dNTP, 400 nM of each primer, 2.5 units of Taq DNA poly-
merase (Invitrogen, U.S.A.). Specific primers recognizing
NA or β2-microglobulin sequences used for in situ ampli-
fication were included in the reaction (amplification size
products of 729 and 100 base pairs, respectively). Amplifi-
cations were carried out using a GeneAmp PCR System
9700 thermal cycler (Applied Biosystems, U.S.A.). The
duplex protocol included 3 minutes incubation at 95°C
followed by 40 cycles of 1 min at 94°C, 1.5 min at 60°C
and 1 min at 72°C. A final extension of 10 minutes at 72°C
was performed. Finally, the duplex PCR products were
separated by electrophoresis on a 2% agarose gel stained
with ethidium bromide and visualized under UV light.
RNA isolation
As a control for in situ determinations, total RNA was
isolated from autopsy samples obtained from patients
with influenza illness using TRIzol reagent according to
the manufacturer’s instructions (Invitrogen). The RNA
preparations were used for cDNA synthesis and Real-
Time PCR.
Preparation of cDNA for Real-Time quantitative PCR
(RTqPCR)
Three micrograms of total RNA were reverse transcribed
in a 20 μl reaction using 100 U SuperScript II Reverse
Transcriptase, following the manufacturer′s specifica-
tions (Invitrogen). In parallel, cDNAs synthesized during
the in situ reverse transcription reaction were recovered
and used for sequencing (Figure 1).
Relative RNA Quantification by RTqPCR
The relative quantification of the A (H1N1) viral load was
determined by RTqPCR using a 7300 Real Time PCR
System (Applied Biosystems, USA). PCRs were processed
through 35 cycles of a 3-step PCR, including 10 sec of
denaturation at 95°C, a 10 sec primer dependent annealing
phase (60°C), and a 10 sec template-dependent elongation
at 72°C. The amplification of each template was performed
in duplicate in one PCR run. The relative viral load was
calculated as the ratio normalized to β2-microglobulin.
RTqPCR data analysis using 2-ΔΔCT method
Real-time PCR was performed on the corresponding
cDNA synthesized from each in situ sample. The data
were analyzed using the equation described by Livak [32].
Validation of the method was performed as previously
reported [32,33].
Results
Clinical features of patients with Influenza
A total of 8 lung samples obtained from patients who died
of pneumonia and respiratory failure influenza-positive
patients (3 females and 5 males) were analyzed using
in situ RT-PCR for influenza A (H1N1) (2009). The most
common symptoms among the infected subjects were
fever over 39 °C (100%), cough (94%), headache (84%),
sore throat (72%), rinorrhea (71%), myalgia (69%), chills
(50%), nasal congestion (44%), and conjunctivitis (40%)
(Table 2).
Expression levels of Neuraminidase A (H1N1) RNA in
patients infected with Influenza
Specific primers recognizing the NA A (H1N1) influ-
enza gene were used to establish expression levels in
RNA samples. NA relative expression levels were deter-
mined in all eight samples using the β2-microglobulin
housekeeping mRNA as internal control (Figure 2a).
Primers and duplex amplification technique were vali-
dated analyzing a large number of nasopharyngeal
swabs obtained from ILI patients (Manuscript in pre-
paration). In addition, all samples were analyzed by
quantitative RTqPCR (Figure 2b).
Ocadiz-Delgado et al. BMC Infectious Diseases 2013, 13:20 Page 5 of 11
http://www.biomedcentral.com/1471-2334/13/20
Table 2 Clinical data of influenza illness patients
Patient Fever Cough Headache Sore throat Rinorrhea Myalgia Chills Nasal
Congestion





P01 + + + + - + + + + + +
P02 + + + + + - + - - + +
P03 + + - - + + - - - + +
P04 + + + + + + + - - + +
P05 + - + - - - - + + + +
P06 + + + - + + - - - + +
P07 + + + + + - + - - + +
P08 + + - + - + - + + + +
Positive Control 1 [A (H1N1) laboratory strain] ND ND ND ND ND ND ND ND ND + +
Positive Control 2 [A (H1N1) positive patient] + + + - - + + + + + ND
Negative Control 1 (Influenza-negative Patient 1) - - - - - - - - - - -
Negative Control 2 (Influenza-negative Patient 2) - - - - - - - - - - -






















NA A (H1N1) influenza gene expression can be detected
in autopsy samples using in situ RT-PCR
The expression pattern of the NA viral gene in lung
samples obtained from patients with pneumonia was
determined by in situ RT-PCR. We detected the expres-
sion of the NA gene in 100% of the samples (Figure 3;
Table 2). As expected, no expression was detected by in
situ RT-PCR in two A (H1N1)-negative patient samples
nor in non-related cells (HeLa cervical cancer cell line;
Figure 3). Relative in situ transcription levels correlated
with those obtained when in vitro RT-PCR assays were
performed. Interestingly, the in situ signal localization
suggests that A (H1N1) influenza virus infects alveolar-
like cells.
Figure 2 Neuraminidase A (H1N1) expression levels in clinical samples. (a) Duplex RT-PCR of A (H1N1) Neuraminidase (NA) and
β2-microglobulin (β2-m) in the eigth A (H1N1)-positive samples (P01-P08). In all experiments, two negative Influenza-like illness patients
[Neg ILI (−) 1, Neg ILI (−) 2] and positive [Pos ILI (+); H1N1 Puerto Rico/Puerto Rico/IvPR8/Puerto Rico; 98% homology] sample were included as
controls. In addition, HeLa cervical cell line and a negative control with no sample (no cDNA) were included [HeLa and Neg (no cDNA),
respectively]. RNA preparations, obtained from nasopharyngeal swabs of A (H1N1) positive cases were assayed using NA or β2-m specific primers
(729 and 100 bp amplification product, respectively). MWM: Molecular weight marker. (b) Neuraminidase A (H1N1) expression levels determined
in the same patient’s samples by quantitative RTqPCR. Viral load results are expressed as Relative Units.
Table 3 List of Influenza A virus sequences detected in clinical specimens
Patient Influenza A subtype Isolate name Homology
P01 A (H1N1) Ontario/Mexico City/Auckland/Jalna 98%
P02 A (H1N1) Ontario/Mexico City/Auckland/Jalna 98%
P03 A (H1N1) Viena/Yaroslavl/Texas 98%
P04 A (H1N1) Ontario/Mexico City/Auckland/Jalna 98%
P05 A (H1N1) New York/San Salvador 98%
P06 A (H1N1) Jalna/Auckland 97%
P07 A (H1N1) Puerto Rico/IvPR8 96%
P08 A (H1N1) Texas/Wisconsin/Roma/Colombia District 98%
Positive Control 1 A (H1N1) Puerto Rico/Puerto Rico/IvPR8/Puerto Rico 98%
Positive Control 2 A (H1N1) A/reassortant/NYMC X-179 (California/07/2009 x NYMC X-157) (H1N1) 99%
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Sample sequencing
Partial sequences of NA gene from A (H1N1)-positive
patients were obtained by the in situ RT-PCR-
sequencing method (Table 3). In all experiments, nega-
tive Influenza-like illness patients [Neg ILI (−)] and two
positive [H1N1 Puerto Rico/Puerto Rico/IvPR8/Puerto
Rico; 98% homology and A/reassortant/NYMC X-179
(California/07/2009 × NYMC X-157) (H1N1), GenBank:
CY058512.1, 99%] controls were included (Tables 2 and
3). In order to avoid contamination and subsequent
positive false results, we have performed sequence
determinations at least in triplicate and we have also
included a negative control without template. Sequence
analysis showed 98% similarity with influenza viruses
reported previously in places such as New York/San
Salvador (98% homology; one of eight patients); Texas/
Wisconsin/Roma/Colombia District (98% homology;
one patient); Ontario/Mexico City/Auckland/Jalna (98%
homology; 3 patients); Viena/Yaroslavl/Texas (98%
homology; one patient). Lower sequence homology was
determined with Jalna/Auckland (97% homology; one
patient) and Puerto Rico/IvPR8 (96% homology; one
patient).
Discussion
In this study we describe a successful method for mo-
lecular detection of A (H1N1) influenza virus RNA in
lung sections obtained from persons who died during
the epidemic outbreak of influenza A (H1N1) 2009 in
Mexico City. Although the current diagnostic technolo-
gies are reasonably effective for sporadic and epidemic
influenza [34], new strategies including more sensitive
and more specific tests have been developed enhancing
not only diagnostic capability but also the need for
Figure 3 Representative images of A (H1N1) RNA detection in lung samples obtained from eight patients with influenza-like illness
and pneumonia using in situ RT-PCR. Tissue was processed and in situ RT-PCR was done with NA specific primers as described in the Methods
section and in Figure 1. Arrows indicate intense cytoplasmic signal in P01-P04 (a) and P05-P08 (b) positive samples in comparison with samples
obtained from two A (H1N1)-negative patients [Neg ILI (−) 1 and 2]. Obtained signal suggested that amplification was positive in pneumocytes
(black empty arrows) or macrophage-like cells (solid arrows; patients P01 and P02) and tracheal epithelium (patient P03). Recovered cDNA was
subsequently amplified and PCR products were validated using sequencing reactions. (a) P01-P04: Tissue samples from patients 1 to 4. Neg ILI (−)
1: Negative Influenza-like illness patient 1. (b) P05-P08: Tissue samples from patients 5 to 8. Neg ILI (−) 2: Negative Influenza-like illness patient 2.
Neg (No RT): Negative controls without reverse transcription reaction. Magnification: 40X and 100X.
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retrospective testing [34]. The main goal of this work
was the standardization of viral RNA genome detection
and viral load determination in patients where sample
collection such as good-quality RNA could not be
performed.
In order to demonstrate that A (H1N1) Neuraminidase
transcript was expressed in infected samples, we decided
to use in situ RT-PCR. This technique combines the ex-
treme sensitivity of PCR with the cell localizing ability
similar to in situ hybridization and allows comparing epi-
thelia with stroma. In situ RT-PCR results demonstrated
that A (H1N1) influenza virus could be detected in the
same tissue as that in which histopathological lesions had
been observed (Figure 3). Furthermore, sequencing data
confirmed that in situ technique was capable to specific-
ally detect viral sequences. Although the primary goal of
this study was to validate the in situ RT-PCR detection of
NA influenza viral gene, we thought that these data may
suggest that Mexico City could have played an important
role for the dissemination of some variants throughout the
world as indicated by the match between the Mexican
samples included in this study and sequences described in
other Countries such as New York, San Salvador, Texas,
Wisconsin, Roma, Colombia District, Ontario, Auckland
and Puerto Rico. In order to establish a phylogenetic ana-
lysis, the entire genome from the viruses should ideally be
sequenced (Neuraminidase gene contains approximately
1,413 bp); the partial NA sequences generated by our
group (729 bp) are of importance as they could provide a
baseline of NA sequences from where the pandemic
emerged. Additional phylogenetic analyses would be
necessary to provide a better understanding of influenza
NA lineages and their evolutionary dynamics, which may
facilitate early detection of newly emerging influenza
viruses and thus improve influenza surveillance and public
health [35].
Recently, immuno-histopathological analyses of lung
autopsy lung from patients with viral pneumonia revealed
that the alveolar epitheliums as well as the alveolar macro-
phages are key target cells infected by influenza [36-42].
Similar conclusions have also been drawn from experi-
ments where ex vivo lung tissue has been infected with the
H5N1 virus [43-45]. Interestingly, morphological analyses
performed in this study suggest that the in situ signal was
detected in alveolar macrophage-like cells; however, the in
situ detection of additional biomarkers would be necessary
to provide evidence of the cellular type that is susceptible
to A (H1N1) viral infection (i.e. bronchial and bronchiolar
epithelial cells, pneumocytes and/or macrophages).
Molecular strategies such as in situ hybridization (ISH)
have been used to identify cells infected with influenza virus
in lung and other tissues [46-49]. One of the main features
of the in situ RT-PCR is to take advantage of the Taq DNA
polymerase to amplify a very low number of copies of a
specific sequence in comparison with ISH in which the
results depend on one-to-one strand recognition. To the
best of our knowledge, the in situ RT-PCR strategy has
been used in a limited number of cases for detecting influ-
enza viral sequences in tissues such as myocardium and
placenta [18,50]. Therefore, this is the first time that in situ
detection of A H1N1 NA sequences is performed in lung
sections. One novel advantage that we have developed per-
forming in situ RT-PCR is the ability of recover and subse-
quently to amplify the cDNA synthesized during the in situ
reverse transcription reaction, this cDNA can be used to
perform nucleic acid sequence analyses as well as to detect
novel biomarkers.
Conclusion
In summary, in situ retrospective detection of influenza
A (H1N1) virus arising in Mexico City could provide im-
portant information to study the natural viral spread of
influenza virus and, if it is possible, to correlate these
data with the emergence of future new pathogenic influ-
enza virus pandemic. Although the majority of pathology
laboratories do not perform in situ RT-PCR techniques,
the development of accurate tests for the detection of
influenza in archival paraffin-embedded samples could
be a complementary tool for the detection of the virus,
enabling the laboratory to provide a prompt, definitive
diagnosis, which would allow clinicians to initiate pre-
ventive methods, implement appropriate infection-control
measures eventually decreasing the incidence of influenza
cases, diminishing duration of hospitalization, reducing
ancillary testing, and decreasing health care costs.
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